梅州如何选择无痛人流方法梅州有子宫内膜炎怎么办,梅州微管可视无痛人流什么时候做好,梅州做安全的打胎总价格,梅州慢性附件炎可以医疗吗,梅州哪个医院看妇科病看的好,梅州做打胎的地方,梅州宫颈糜烂能怀孕吗

BALI, Indonesia, Nov. 19 (Xinhua) -- Leaders of China, Japan and South Korea met here Saturday to exchange views on trilateral cooperation and regional and international issues of common concern.Chinese Premier Wen Jiabao, Japanese Prime Minister Yoshihiko Noda and South Korean President Lee Myung-bak were meeting on the occasion of a series of meetings for East and Southeast Asian leaders in this Indonesian resort city on Friday and Saturday.Speaking at the meeting, Wen said the cooperation between the three nations currently had good momentum, which was not only in line with the interests of the three sides but also contributed to the stability and development of the Asia and the world.Chinese Premier Wen Jiabao (L), Japanese Prime Minister Yoshihiko Noda (C) and Republic of Korea (ROK) President Lee Myung-Bak pose for photos during the Trilateral Summit Meeting for leaders of the three nations in Bali, Indonesia, Nov. 19, 2011.As the coordinator of next year's China-Japan-South Korea cooperation, China would like to further enhance high-level exchanges, policy coordination and strategic trust between the three countries, providing political impetus and promoting more advancement in trilateral cooperation, Wen said.He said next year marked the 40th anniversary of the normalization of diplomatic relations between China and Japan, and the 20th anniversary of the establishment of diplomatic relations between China and South Korea.In the meeting, Wen proposed the joint research into a free trade area between the three countries be completed this year, and negotiations start in 2012.Wen also suggested enhancing trilateral cooperation in the fields of transportation, finance and environmental protection, among many others.Also speaking at the meeting, the Japanese prime minister and the South Korean president said the cooperation between the three nations had seen remarkable achievement and its prospects were promising.The three sides should continue to deepen their exchanges and cooperation in various fields including economy and trade, finance, investment, disaster relief, culture, education and tourism, and strengthen the coordination in regional and international issues to promote common development, according to them.During the meeting, the three leaders also exchanged views on other regional and international issues of common concern.

BEIJING, Oct. 27 (Xinhuanet) -- A new study shows that it's not simply a lack of willpower that explains weight regain but hormones keep one insisting on eating, a persistent biological urge. As any dieter knows, it's hard to keep weight off. Weight regain is a familiar problem for dieters. The research appears in Thursday's issue of the New England Journal of Medicine. To study what drives it, Proietto and his colleagues enrolled 50 overweight or obese patients in Australia in a 10-week diet program. On average, the participants lost almost 30 pounds in the 10 weeks - faster than the standard advice of losing a pound or two per week. Even so, they gained an average of 12 pounds back over the next year. The scientists checked the blood levels of nine hormones known to influence appetite - and found that even a year after the end of the weight-loss program, six of the hormones were still out of whack. People who regain weight should not be harsh on themselves, as eating is our most basic instinct, study author Joseph Proietto of the University of Melbourne in Australia said. It's better not to gain weight than to try to lose it.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

SAN FRANCISCO, Nov. 4 (Xinhua) -- Google is mulling a plan to offer paid cable-TV services to consumers, a move that could flare up a new wave of competition in the traditional TV business, U.S. media reported on Friday.According to The Wall Street Journal, the Internet search giant has considered adding video and phone services to a previously announced high-speed Internet service in two U.S. cities.People briefed on the plan told the newspaper that Google has discussed distributing major TV channels from companies like Walt Disney, Time Warner and Discovery Communications as part of the video service. The discussions were still exploratory and no final decisions have been made, said the report.Google said it does not comment on rumor or speculation.Whether it is a speculation or not, the reported plan reflects possible innovation and revolution for the traditional TV experience with the growth of high-speed Internet, which may become another lucrative battlefield all the technology giants will fight for.With the growth of home and mobile broadband services, more and more video contents become available for rental, purchase and streaming on desktop computers, tablet computers and smartphones.Competitions on the video streaming market have been increasingly fierce this year, among such services as Apple's iTunes, Amazon's Prime Video, NetFlix, Hulu Plus and Vudu, which is owned by Wal-Mart.Cable companies, facing a grim picture of being kicked out in the decades to come, also fought back with their own mobile apps and online streaming services.A new Steve Jobs biography revealed that the late Apple co- founder had been working on an Apple television."It would be seamlessly synced with all of your devices and with iCloud. It will have the simplest user interface you could imagine. I finally cracked it," Jobs told biographer Walter Isaacson in the book.Some analysts said the introduction of an Apple smart TV could bring a 100-billion-U.S.-dollar revenue opportunity for the Cupertino, California-based company.Last Friday, Google-owned YouTube announced a plan to launch 100 channels on its site with original professionally produced content. A new version of Google TV was also launched with new search tools that expand results from shows on cable to web-based services like NetFlix and Amazon.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.